Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Aggressive Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- DRUG: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160
- OTHER: Pharmacological Study
Sponsor
Mayo Clinic
Collaborators